Company Directory / pharmaceuticals
PrivateFor profitpharmaceuticalsRedwood City, United States
Ashvattha Therapeutics
Ashvattha Therapeutics is a biotechnology company that creates products that selectively target and treat human diseases.
- Founded
- 2015 11 years ago
- Staff
- 11-50 band, as listed
- Followers
- - on LinkedIn
- Funding
- $98M as listed, currency not stated
Set against six million companies
Size
11-50 people: larger than 33% of companies with a size listed
Age
11 years old.
Reach
Website ranked #7,861,219 in the world for traffic, about 685 visits a month.
What it does
BiotechnologyHealth CarePharmaceuticalTherapeutics
Funding, as listed
$98M currency not stated
- Rounds4
- LatestSeries b, Apr 2023
- Investors17, 2 leading
What the source datasets report. We have not watched these rounds ourselves.
Every detail we hold
Everything the source datasets list about Ashvattha Therapeutics, field by field. Contact details are held but never shown.
The company
- Name
- Ashvattha Therapeutics
- Type
- For profit
- Status
- Private
- Founded
- 2015
- Founders
- Jeffrey Cleland, Justin Hanes, Kannan Rangaramanujam, Sujatha Kannan
- Industry
- pharmaceuticals
- Categories
- Biotechnology, Health Care, Pharmaceutical, Therapeutics
Where
- City
- Redwood City
- Country
- United States
- Markets
- San Francisco Bay Area, Silicon Valley, West Coast, Western US
Size and reach
- Staff band
- 11-50
- Web traffic rank
- #7,861,219
- Monthly web visits
- 685
Funding, as listed
- Total
- 98,000,000 (currency not stated)
- Rounds
- 4
- Latest round
- Series b
- Latest round date
- Apr 2023
- Investors
- 17
- Lead investors
- 2
- Listing status
- private
About this record
- Sources
- Crunchbase
- Last imported
- Sept 2026
Growth, as the source summarises it
Ashvattha Therapeutics may be growing as indicated by the CEO's discussion of the company's unique nanomedicine technology, which suggests ongoing innovation and potential for market impact. While the articles do not provide direct financial data for Ashvattha Therapeutics, the mention of the company by its President and CEO in the context of its technology advancement is a positive qualitative indicator. Additionally, the broader market for Wet-Age Related Macular Degeneration, a condition that Ashvattha Therapeutics' products may target, is predicted to observe significant growth by 2032, which could imply a favorable market environment for the company's growth.
Summaries written by the source dataset, not by us, and not checked.
Companies like it
pharmaceuticals in United States.
From the company datasets we hold (Crunchbase, LinkedIn and Apollo listings), as listed there; 1,637,054 companies in United States and 5,926,251 in all. We hold no contact details for public display. Correct this, or ask for it to be removed.